Zevra Therapeutics (ZVRA) asked shareholders in a preliminary proxy statement late Monday to vote down the director nominees proposed by activist investor Daniel J. Mangless and elect the two incumbent members at the next annual shareholders meeting.
One member Mangless nominated is former Zevra chief executive Travis Mickle, who stepped down from the company in January 2023, but continued in an advisory role at Zevra until last October. Mickle's association with the company means he cannot be considered independent.
Mangless also nominated Arthur Regan, who is founder of a proxy solicitation firm he hired to assist with a successful bid to replace several other board members in 2023.
Zevra is asking shareholders to return Wendy Dixon and Tamara Favorito to the board. Dixon has been a board member since 2023 and Favorito began in 2021. The company has not yet set a date for its 2025 annual meeting.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。